Immunovant (IMVT) Stock Forecast & Price Target

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

$28.22

-0.10 (-0.35%)

(As of 04/19/2024 ET)

Immunovant Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 17 Analyst Ratings

Analysts' Consensus Price Target

$48.00
70.09% Upside

High Forecast	$57.00
Average Forecast	$48.00
Low Forecast	$32.00

Type	Current Forecast 4/20/23 to 4/19/24	1 Month Ago 3/21/23 to 3/20/24	3 Months Ago 1/20/23 to 1/20/24	1 Year Ago 4/20/22 to 4/20/23
Consensus Rating	Buy	Buy	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	16 Buy rating(s)	14 Buy rating(s)	8 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$48.00	$47.88	$45.07	$22.91
Predicted Upside	70.09% Upside	34.64% Upside	31.77% Upside	51.08% Upside

Get Immunovant Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

IMVT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IMVT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Immunovant Stock vs. The Competition

Type	Immunovant	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.68	2.49
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	70.09% Upside	983.83% Upside	11.91% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/28/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$50.00	+53.75%
3/25/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$48.00	+47.69%
3/13/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+58.73%
2/20/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$51.00	+37.36%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$55.00	+45.50%
1/12/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
Get the Latest News and Ratings for IMVT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.
12/21/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$49.00 ➝ $51.00	+31.61%
12/21/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$47.00 ➝ $51.00	+40.96%
12/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+25.69%
12/1/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$55.00 ➝ $56.00	+39.83%
10/24/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$28.00 ➝ $57.00	+64.74%
9/27/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$32.00 ➝ $48.00	+14.75%
9/27/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$33.00 ➝ $50.00	+25.13%
9/27/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$33.00 ➝ $48.00	+20.12%
9/26/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$40.00	+7.79%
7/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$28.00 ➝ $34.00	+47.00%
7/10/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Barcus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:47 PM ET.

IMVT Price Target - Frequently Asked Questions

What is Immunovant's consensus rating and price target?: According to the issued ratings of 17 analysts in the last year, the consensus rating for Immunovant stock is Buy based on the current 17 buy ratings for IMVT. The average twelve-month price prediction for Immunovant is $48.00 with a high price target of $57.00 and a low price target of $32.00. Learn more on IMVT's analyst rating history.
Do Wall Street analysts like Immunovant more than its competitors?: Analysts like Immunovant more than other Medical companies. The consensus rating for Immunovant is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how IMVT compares to other companies.
Does Immunovant's stock price have much upside?: According to analysts, Immunovant's stock has a predicted upside of 36.33% based on their 12-month stock forecasts.

What analysts cover Immunovant?: Immunovant has been rated by JPMorgan Chase & Co., Oppenheimer, The Goldman Sachs Group, Truist Financial, and Wolfe Research in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:IMVT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immunovant (IMVT) Stock Forecast & Price Target

Immunovant Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

IMVT Analyst Ratings By Month

IMVT Price Targets by Month

Immunovant Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

IMVT Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info